Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
Jashin J WuXiaoying JiaYang ZhaoJustin CarricoThor-Henrik BrodtkorbAlan MendelsohnSimon LowrySteven Richard FeldmanApril ArmstrongPublished in: The Journal of dermatological treatment (2020)
Tildrakizumab was among the most cost-effective first-line treatments for moderate-to-severe psoriasis and was more cost-effective than risankizumab, secukinumab, guselkumab, ixekizumab, adalimumab, ustekinumab, etanercept, and certolizumab pegol.